Laurus Labs has said it has received the license from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.
“Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.
- Govt plans new route connecting Noida airport to NH-34
- India Ranks Third in Global Fintech Funding, Despite 33% Drop in 2024
- India’s Retail Inflation Drops to 5.22% in December, Food Inflation at 8.39%
- Donald Trump Inauguration: Xi Jinping Invited, S Jaishankar to Represent India
- What Is Currency Appreciation: Working & Cause Of Currency Appreciation
On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet. Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.
